| |JULY 20268TOP STORIESCOVID PREPAREDNESS IN ODISHA GETS STRONGER AS CASES RISE NEARBYINDIA'S PHARMA FUTURE HINGES ON BIOSIMILARS MANUFACTURINGEMCURE TIGHTENS GRIP ON GENNOVA WITH RS 232 CRORE ACQUISITIONJEMPERLI SUCCESS RAISES HOPE IN ADVANCED RECTAL CANCEROXFORD STARTS WORLD'S FIRST HUMAN TRIAL FOR EBOLA VACCINEEISAI-BIOGEN GAIN EDGE IN ALZHEIMER'S DRUG MARKETCOVID preparedness has become a key focus in Odisha after fresh COVID-19 cases were reported in neighboring Andhra Pradesh. The state has increased COVID surveillance and COVID-19 testing to prevent any possible spread. Officials said there are no positive COVID-19 cases in Odisha.However, health authorities are taking preventive steps to stay prepared. COVID preparedness has been strengthened ahead of the upcoming Rath Yatra, which is expected to draw large crowds from across the country. The state government has directed health officials to closely monitor the situation. Special attention is being given to border districts that share boundaries with Andhra Pradesh. Authorities want to ensure any suspected case is detected early. POThe Indian Pharma Industry is moving towards a biosimilars manufacturing growth phase. Earlier this year, India was the subject of a global collaboration that reflects growing international trust in its abilities. OneSource Specialty Pharma has partnered with Germany-based Formycon AG. The deal focuses on manufacturing biosimilars for global markets.This development reflects India's cost advantage and technical expertise. It also shows strong global investments in pharma manufacturing. India is gradually emerging as an attractive destination for biologics manufacturing. This partnership paves the way for future expansion in Indian pharmaceutical exports. It also enhances India's Emcure has tightened its grip on Gennova with a Rs 231.8 crore acquisition. The deal will make Gennova a wholly owned subsidiary of the company. Emcure will buy the remaining 12.05 percent stake through an all-cash transaction. The move supports the company's One Emcure strategy.It also aims to simplify operations and strengthen its biologics business. The acquisition comes with a leadership change and a planned separation of Gennova's mRNA business. Emcure Pharmaceuticals will acquire the remaining 12.05 percent A major breakthrough in the treatment of advanced rectal cancer has emerged as innovative immunotherapy drugs continue to reshape oncology. GlaxoSmithKline's Jemperli has demonstrated remarkable success in a mid-stage clinical trial. This offers new hope for patients with limited treatment options.Advanced rectal cancer remains a significant global health burden, with rising incidence rates and complex treatment challenges. The latest results highlight how targeted therapies are transforming survival prospects and quality of life. This milestone reinforces the growing importance of precision medicine and immunotherapy in tackling cancers that were once difficult to treat effectively. POThe Oxford Ebola vaccine has reached a major milestone. The University of Oxford has started the world's first human trial for a vaccine against the Bundibugyo Ebola virus. The Oxford Ebola vaccine trial aims to close a long-standing gap in The Alzheimer's drug market is witnessing a significant strategic shift as Eisai and Biogen strengthen their competitive position. As the new FDA approval that allows at-home initiation of their therapy. This development signals a broader transformation in how complex biologics are delivered, moving beyond traditional hospital-based infusion systems.By enabling patients to begin treatment outside clinical settings, the companies are not only improving accessibility but also redefining market dynamics. The move reflects a growing emphasis on patient-centric innovation, lifecycle management, and differentiated delivery strategies that can expand reach, improve adherence, and ultimately reshape the global Alzheimer's treatment landscape. POglobal position in the biosimilars manufacturing value chain. POstake in Gennova Biopharmaceuticals for Rs 231.8 crore. The company disclosed the deal in a regulatory filing. PO
< Page 7 | Page 9 >